Yann Abraham

Yann Abraham, PhD, is the Head of Drug Discovery at DeepLife, where he leads the application of digital twin technology to drive drug repositioning and indication expansion efforts. Before joining DeepLife in 2025, Yann worked at the intersection of data science and translational research at Johnson & Johnson and Novartis, leading the development of innovative computational methods to support target & biomarker identification using single cell analysis. He began his professional career at Cellzome, a biotechnology company that is now part of GSK. With over 20 years of experience in the biotechnology and pharmaceutical industries, Yann brings a strong focus on unmet medical need and impact for the patient. Yann holds a PhD in Biochemistry from the Université Paris XI Orsay.